Skip to main content

5 Result(s)

within H. Maecke Remove this filter

and

  1. No Access

    Article

    Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

    Gallium-68 is a metallic positron emitter with a half-life of 68 min that is ideal for the in vivo use of small molecules, such as [68Ga-DOTA,Tyr3]octreotide, in the diagnostic imaging of somatostatin receptor-po...

    P. Antunes, M. Ginj, H. Zhang, B. Waser… in European Journal of Nuclear Medicine and M… (2007)

  2. No Access

    Article

    Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours

    F. Forrer, J. Mueller-Brand, H. Maecke in European Journal of Nuclear Medicine and M… (2005)

  3. No Access

    Article

    Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study

    We have previously presented preliminary observations on targeting somatostatin receptor-positive malignant gliomas of all grades by local injection of the radiolabelled peptidic vector 90Y-DOTATOC. We now repor...

    T. Schumacher, S. Hofer, K. Eichhorn… in European Journal of Nuclear Medicine and M… (2002)

  4. No Access

    Article

    Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data

    Somatostatin (SMS) scintigraphy is widely used for the detection and staging of neuroendocrine tumours. Because of its superior imaging properties, there is growing interest in the use of positron emission tom...

    M. Hofmann, H. Maecke, A. Börner, E. Weckesser… in European Journal of Nuclear Medicine (2001)

  5. No Access

    Chapter

    Copper-67 labeled mAb chCE7 as a potential therapeutic agent for neuroblastoma: improved biodistributions of copper-67-chCE7 F(ab’)2

    Neuroblastoma relapses associated with bone marrow infiltrations are considered a favorable therapeutic setting for radioimmunotherapy (RIT), because access of radiolabeled, tumor specific monoclonal antibodie...

    I. Novak-Hofer, K. Zimmermann, H. Amstutz… in Radioactive Isotopes in Clinical Medicine … (1997)